Market Cap | 183.50M | P/E | 559.50 | EPS this Y | - | Ern Qtrly Grth | - |
Income | 860.48k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 10.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 12.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -21.00% |
Recommedations | - | Quick Ratio | 0.20 | Shares Outstanding | 13.21M | 52W Low Chg | 21.00% |
Insider Own | - | ROA | - | Shares Float | 11.96M | Beta | - |
Inst Own | 72.37% | ROE | - | Shares Shorted/Prior | 3.95K/5.47K | Price | 11.19 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 127,598 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 77,641 | Change | -4.44% |
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on business in the life sciences industry in Europe. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.